39results about How to "Improve in vivo activity" patented technology

A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery.

The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.

A fusion protein (I), where a carboxy terminal peptide (CTP) of thrombopoietin (TPO) is fused with the carboxy terminal of human erythropoietin (EPO), is new. Independent claims are also included for the following: (1) nucleic acid (II) encoding (I); and (2) preparing (I). - ACTIVITY : Antianemic. No biological data is given. - MECHANISM OF ACTION : Stimulator of production and differentiation of red blood cells.

The present invention relates to a method for producing large amounts of human growth factors from human adipose-derived stem cells. More specifically, the invention provides a method capable of synthesizing human growth factors in significantly large amounts by culturing adipose-derived stem cells extracted from human adipose cells in suitable media and conditions. Also, stem cell culture media produced according to the method of the invention, and human growth factors isolated from the culture media, can be advantageously used as raw materials for drugs and cosmetics.

The invention relates to nanoparticles as well as a preparation method and application thereof, and belongs to the field of biological medicines. The nanoparticle comprises a 5-methylpyrimidine-2, 4 (1H, 3H)-diketone derivative and an auxiliary material. The nanoparticles can entrap nucleic acid, and have the advantages of low toxicity, high entrapment efficiency, good transfection effect and good bioavailability. The preparation method is simple to operate, low in cost, environment-friendly and beneficial to industrial production.

The invention discloses a maleimide-polyglutamic acid-aspartic acid polymer. The maleimide-polyglutamic acid-aspartic acid polymer is formed by the covalent bonding of a gamma-polyglutamic acid-aspartic acid polymer and amine compounds containing maleimide groups, wherein the bonding is realized by forming an amido bond between a free carboxyl group of the gamma-polyglutamic acid-aspartic acid polymer and amino groups on the amine compounds containing the maleimide groups under the coaction of a condensing agent and a catalyst. The invention also discloses a maleimide-polyglutamic acid-aspartic acid composite and a preparation method and application thereof. By coupling biological active molecules with a sulfydryl group, the stability and in-vivo activity of the maleimide-polyglutamic acid-aspartic acid polymer can be improved, and the in-vivo half life of the maleimide-polyglutamic acid-aspartic acid polymer can be prolonged; and meanwhile, the polymer which is coupled with targetingmolecules with the sulfydryl group and is combined with an anti-tumor medicine can become a polymer medicine with active targeting.

Disclosed are an IgG-like long-acting immune fusion protein and the use thereof. The IgG-like long-acting immune fusion protein consists of an effector molecule and a constant region of an IgG antibody, and the effector molecule is linked to the constant region of the IgG antibody by means of a linker peptide; the effector molecule is a protein capable of exerting physiological functions in the body; and the constant region of the IgG antibody is a structure of the IgG antibody with two heavy chain variable regions and two light chain variable regions removed.

The invention discloses a fused protein. The first part of the fused protein is recombinant anthrax toxin receptor CMG2, the second part is recombinant human serum albumin, the first part and the second part are connected by a linker peptide, the half-life in vivo of the fused protein is increased by nearly 20 times compared with the recombinant anthrax toxin receptor CMG2. Also, the fused protein has very good in vivo activity, and can fully protect toxin attacked experimental animals.

The invention discloses an Escherichia coli strain for preparing active short peptides, the strain is Escherichia coli; the preservation name is Escherichia coli; it is preserved in CGMCC, General Microorganism Center of China Microbiological Culture Preservation Management Committee, and the preservation address is Chaoyang, Beijing No. 3, No. 1 Yard, Beichen West Road, District; date of deposit: October 24, 2014; deposit number: CGMCCNo.9842. The Escherichia coli bacterial agent prepared by the Escherichia coli described in the present invention. The present invention is an Escherichia coli strain capable of producing active short peptides with high in vivo activity and low cost.

The present invention relates to β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives (I) and a method for preparing same and the use in the aspects of preventing and treating plant viruses, fungicides and insecticides. For the meaning of each group in formula (I) see the description. The β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives of the present invention show a particularly ourstanding anti-plant virus activity, and also have fungicidal and insecticidal activities.

The invention discloses that oleanolic acid and ursolic acid are used in the preparation and regulation of vitamin D 3 Applications in drugs that metabolize enzymatic activity. The present invention has discovered that the natural product oleanolic acid and ursolic acid are mixed with a mass ratio of 3:1, which has the function of regulating vitamin D 3 The role of metabolic enzyme activity, thereby increasing the active vitamin D in the body 3 (1,25(OH) 2 D. 3 ) levels, improve calcium balance and enhance bone density. On this basis, oleanolic acid and ursolic acid are encapsulated with natural high-molecular zein protein to improve their stability under external environmental conditions and increase oral bioavailability. At the same time, the slow-release technology of nanoparticles alleviates the Toxic effects of high-dose oral administration of oleanolic acid and ursolic acid on tissue cells. May be used to treat or prevent active vitamin D 3 Osteoporosis, diabetes, metabolic syndrome, cardiovascular disease, hyperparathyroidism, renal failure, psoriasis, cancer, and immune disease due to decreased synthesis and deficiency.

The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS moecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO).